An observational study in PCOS and Reproductive Age, sponsored by Jagiellonian University. Recruiting at 1 site in Poland. Open to female participants aged 18 Years to 45 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-03-18.
Sponsored by Jagiellonian University · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 27 studies in Insulin Resistance with a site in Poland — 4 open to participants now, 4 under way, none of them phase 3. Insulin Resistance · Poland.
Among the 27 studies in Insulin Resistance with a site in Poland, this one is one of 5 that started in 2025, is one of 6 observational ones, and was the 21st registered.
2,974 studies on the registry are indexed under Insulin Resistance; 336 are open to participants now.
Browse Insulin Resistance studies →4 of the 27 studies in Insulin Resistance with a site in Poland are open now. Recruiting first, the newest first:
University of Applied Sciences in Nowy Targ · Sites in Poland
Ages 18–35 · Women only · Healthy volunteers
Jagiellonian University · Sites in Poland
Ages 18–45 · Women only · Healthy volunteers
Jagiellonian University · Sites in Poland
Ages 18–45 · Women only · Healthy volunteers
A study can be open while its sites in Poland have not opened yet or have stopped. Only those recruiting at a site in Poland →
Of the 241 Insulin Resistance studies recruiting now, 52 (22%) set no upper age limit and 157 (65%) stop at 75 or younger; 28 take children under 18; 112 take healthy volunteers.
This study: 18 Years to 45 Years · female · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
27 studies; the count open now beside each. This study's row is marked.
First in 2006; this study’s year is marked. 5 started in 2025.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 300 is above the median of 81 across 480 observational studies indexed under Insulin Resistance.
Median enrollment 78 across the 21 interventional studies, 155 across the 6 observational. Of the 16 that completed or were terminated, 5 (31%) have results posted.
This tab as a report to print or save as PDF → With an account.
5 of 27 have an industry lead sponsor. The 10 most frequent:
Jagiellonian University is the lead sponsor of 161 studies on the registry; 34 are open to participants now.
Jagiellonian University has 3 studies filed under Insulin Resistance — fewer than ten, so there is no comparison to draw.
1 of the studies in Insulin Resistance with a site in Poland that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07917364University of Applied Sciences in Nowy TargAsprosin and miRNA Expression in Young Women With Metabolic Syndrome | 2027-03 |
Add it to your calendar (.ics) → With an account.
Among the 27 studies in Insulin Resistance with a site in Poland, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The aim of the study is to compare the concentrations of leptin, resistin, and omentin-1 in women across three research groups: those with polycystic ovary syndrome without insulin resistance, those with polycystic ovary syndrome with insulin resistance, and women without polycystic ovary syndrome.
Polycystic ovary syndrome (PCOS) is the most prevalent endocrinopathy among reproductive-age women, characterized primarily by insulin resistance (IR), which has a prevalence of 35% to 80%. Metabolic disturbances associated with PCOS contribute to a higher incidence of cardiovascular diseases and endometrial cancer prior to menopause. The hyperinsulinemic-euglycemic clamp study is regarded as the gold standard for assessing insulin sensitivity; however, its clinical application is limited. Alternative assessments, such as the Homeostasis Model Assessment of Insulin Resistance (HOMA-IR) and fasting insulin or glucose tolerance tests, provide limited clinical utility. Therefore, there is a pressing need for the identification of more precise and universal markers of insulin resistance. There is a need to elucidate the precise role of adipokines in the etiology of PCOS and their association with insulin resistance, which is responsible for the development of adverse health-related complications.
The aim of the study is to measure and compare the concentrations of selected adipokines: leptin, resistin, omentin-1 across three research groups: those with polycystic ovary syndrome without insulin resistance, those with polycystic ovary syndrome with insulin resistance, and women without polycystic ovary syndrome.
The tests will be performed using immunoenzymatic methods (ELISA) and the Erba XL biochemical analyzer.
The concentrations of the investigated substances will be measured and compared within the three research groups.
Statistical analysis will be conducted using SPSS Statistics software.
women aged 18-45 years managed for menstrual irregularities or routine check-up
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
Autoimmune disease
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Polycystic ovary syndrome + insulin resistance
Diagnostic Test: Leptin concentration in blood serum · Diagnostic Test: Resistin concentration in blood serum · Diagnostic Test: Omentin-1 concentration in blood serum
Polycystic ovary syndrome + no insulin resistance
Diagnostic Test: Leptin concentration in blood serum · Diagnostic Test: Resistin concentration in blood serum · Diagnostic Test: Omentin-1 concentration in blood serum
Women without PCOS (control)
Diagnostic Test: Leptin concentration in blood serum · Diagnostic Test: Resistin concentration in blood serum · Diagnostic Test: Omentin-1 concentration in blood serum
Fasting plasma leptin concentration measurement with results expressed in pg/ml and comparison across all study arms
Fasting plasma resistin concentration measurement with results expressed in pg/ml and comparison across all study arms
Fasting plasma omentin-1 concentration measurement with results expressed in pg/ml and comparison across all study arms
Comparison of resistin concentration in three study groups
Measurement and comparison of mean fasting plasma resistin concentration expressed in pg/ml in three study groups
Time frame: up to 6 months
Comparison of leptin concentration three study groups
Measurement and comparison of mean fasting plasma leptin concentration expressed in pg/ml in three study groups
Time frame: up to 6 months
Comparison of omentin-1 concentration in three study groups
Measurement and comparison of mean fasting plasma omentin-1 concentration expressed in pg/ml in three study groups
Time frame: up to 6 months
Started Jan 2025 (actual). Primary completion is estimated for Dec 2027, 35 months after the start.
Of 130 non-industry observational studies under Insulin Resistance, half reached primary completion within 53 months of starting (the median), counting those still running; a quarter within 18 and three quarters within 142. This study's planned 35 months is below that.
Counting every sponsor, half of 133 studies reached it within 53 months; a quarter within 18 and three quarters within 142.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.